ArticleJournal of materials chemistry. B2018
The in vivo fates of plant viral nanoparticles camouflaged using self-proteins: overcoming immune recognition.
Article in Journal of materials chemistry. B, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Nondestructive tracking of viral infections by viral protein-initiated fluorescent sensors.Journal of virology · 2026Article
- Plant-Derived Anti-Cancer Therapeutics and Biopharmaceuticals.Bioengineering (Basel, Switzerland) · 2024Review
- Assembly of Protein Cages for Drug Delivery.Pharmaceutics · 2022Review
- Photothermal immunotherapy of melanoma using TLR-7 agonist laden tobacco mosaic virus with polydopamine coat.Nanomedicine : nanotechnology, biology, and medicine · 2022Article
- TheBiomaterials science · 2021Article
- The pharmacology of plant virus nanoparticles.Virology · 2021Review
- Recent Advances in Understanding the Protein Corona of Nanoparticles and in the Formulation of "Stealthy" Nanomaterials.Frontiers in bioengineering and biotechnology · 2020Review
- Developing Protein-Based Nanoparticles as Versatile Delivery Systems for Cancer Therapy and Imaging.Nanomaterials (Basel, Switzerland) · 2019Review
- Development of improved dual-diazonium reagents for faster crosslinking of tobacco mosaic virus to form hydrogels.RSC advances · 2019Article
- Delivery of siRNA therapeutics using cowpea chlorotic mottle virus-like particles.Biomaterials science · 2019Article
- Future of cancer immunotherapy using plant virus-based nanoparticles.Future science OA · 2019Review
- Polydopamine-decorated tobacco mosaic virus for photoacoustic/magnetic resonance bimodal imaging and photothermal cancer therapy.Nanoscale · 2019Article
- Cancer Theranostic Applications of Albumin-Coated Tobacco Mosaic Virus Nanoparticles.ACS applied materials & interfaces · 2018Article
- Delivery of thrombolytic therapy using rod-shaped plant viral nanoparticles decreases the risk of hemorrhage.Nanoscale · 2018Article
- Bioinspired Shielding Strategies for Nanoparticle Drug Delivery Applications.Molecular pharmaceutics · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Nanoparticles offer a promising avenue for targeted delivery of therapies. To slow clearance, nanoparticles are frequently stealth-coated to prevent opsonization and immune recognition. Serum albumin (SA) has been used as a bio-inspired stealth coating. To develop this shielding strategy for clinical applications, it is critical to understand the interactions between the immune system and SA-camouflaged nanoparticles. This work investigates the in vivo processing of SA-coated nanoparticles using tobacco mosaic virus (TMV) as a model system. In comparing four different SA-formulations, the particles with high SA coverage conjugated to TMV via a short linker performed the best at preventing antibody recognition. Irrelevant of the coating chemistry, all formulations led to similar levels of TMV-specific antibodies after repeat administration in mice; importantly though, SA-specific antibodies were not detected and the TMV-specific antibodies were unable to recognize shielded SA-coated TMV. Upon uptake in macrophages, the shielding agent and nanoparticle separate, where TMV trafficked to the lysosome and SA appears to recycle. The distinct intracellular fates of the TMV carrier and SA shielding agent explain why anti-TMV but not SA-specific antibodies are generated. This work characterizes the outcomes of SA-camouflaged TMV after immune recognition, and highlights the effectiveness of SA as a nanoparticle shielding agent.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.